Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05577845
NA
5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)
Sponsor: Seoul National University Hospital
View on ClinicalTrials.gov
Summary
Safety \& Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial
Official title: Safety & Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
212
Start Date
2023-03-27
Completion Date
2032-12
Last Updated
2023-04-25
Healthy Volunteers
No
Conditions
Interventions
DRUG
Ramosetron
Ramosetron, 4 weeks
Locations (1)
Seoul National University Hospital
Seoul, Jongro-gu, South Korea